Activation of α7 nicotinic acetylcholine receptor ameliorates HIV-associated neurology and neuropathology

• Published in: Brain (London, England : 1878) England : 1878), 2021-12, Vol.144 (11), p.3355-3370
• Main Authors: Zhao, Xiaojie, Wilson, Kelly, Uteshev, Victor, He, Johnny J
• Format: Article
• Language: English
• Subjects: AIDS Dementia Complex - metabolism; alpha7 Nicotinic Acetylcholine Receptor - metabolism; Animals; Mice; Mice, Inbred C57BL; Mice, Transgenic; Original; tat Gene Products, Human Immunodeficiency Virus - toxicity
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awab251

HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy are primarily manifested as impaired behaviours, glial activation/neuroinflammation and compromised neuronal integrity, for which there are no effective treatments currently available. In the current study, we used doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, and determined effects of PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) on Tat-induced behavioural impairments and neuropathologies. We showed that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. Using α7 nAChR knockout mice, we showed that α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, we showed that inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor exacerbated Tat neurotoxicity in iTat mice. Last, we used primary mouse cortical individual cultures and neuron-astrocytes co-cultures and in vivo staining of iTat mouse brain tissues and showed that glial activation was directly involved in the interplay among Tat neurotoxicity, α7 nAChR activation and the p38 MAPK signalling pathway. Taken together, these findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggested that α7 nAChR modulator PNU-125096 holds significant promise for development of therapeutics for HAND.